Delisting risk
Medicus Pharma (MDCX)
Develops clinical-stage therapies for skin cancer, urology, oncology, and women’s health.
$0.2600
Pre-market+0.00 (+0.89%)
At close$0.2577(+2.59%)
Something off on this page? Send us feedback.
Next report
Nov 13, 2026
estimated · in 71 days
EPS estimate
−$0.17
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.18−$0.42−$0.43−$0.65−$0.82−$0.31−$0.21Pending
Estimate−$0.32−$0.23−$0.39−$0.38−$0.32−$0.18−$0.13−$0.17
Surprise+43.8%−82.6%−10.3%−71.1%−156.2%−72.2%−64.7%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.17 | — | — |
| Aug 2026 | −$0.13 | −$0.21 | −64.7% |
| May 2026 | −$0.18 | −$0.31 | −72.2% |
| Mar 2026 | −$0.32 | −$0.82 | −156.2% |
| Nov 2025 | −$0.38 | −$0.65 | −71.1% |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.17 | — | — | — | — | — | — |
| Aug 12, 2026 | −$0.13 | −$0.21 | −64.7% | — | — | — | +6.9% |
| May 14, 2026 | −$0.18 | −$0.31 | −72.2% | — | — | — | −10.7% |
| Mar 25, 2026 | −$0.32 | −$0.82 | −156.2% | — | — | — | −5.7% |
| Nov 14, 2025 | −$0.38 | −$0.65 | −71.1% | — | — | — | +4.6% |
The latest year is open to everyone — the 9 quarters behind it read with an account. Sign in | |||||||
| Aug 11, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 28, 2025 | |||||||
| Nov 22, 2024 | |||||||
| Aug 22, 2024 | |||||||
| May 30, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||